Archive: 13/04/2020

FDA approves first ever treatment for neurofibromatosis

The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1). The FDA's ...

page 3 from 13